Z-338

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Feb 1, 2006 → —

NCT ID

NCT00298194

About Z-338

Z-338 is a phase 2 stage product being developed by Zeria Pharmaceutical for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00298194. Target conditions include Dyspepsia.

What happened to similar drugs?

3 of 16 similar drugs in Dyspepsia were approved

Approved (3) Terminated (3) Active (12)

✅esomeprazoleAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

✅Tegaserod and PlaceboNovartisApproved

🔄YM443Astellas PharmaPhase 3

🔄Cinitapride + domperidoneEisaiPhase 3

🔄Z-338Zeria PharmaceuticalPhase 3

🔄Imonogas + EspumisanJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01973790	Phase 3	Completed	Mar 1, 2014	Apr 1, 2017	Dyspepsia
NCT00458328	Phase 2	Completed	Apr 1, 2007	Jul 1, 2010	Functioanl Dyspepsia
NCT00333372	Phase 2	Completed	Apr 1, 2006	—	Functional Dyspepsia
NCT00323817	Phase 2	Completed	Apr 1, 2006	Oct 1, 2009	Functional Dyspepsia
NCT00298194	Phase 2	Completed	Feb 1, 2006	—	Dyspepsia

Competing Products

20 competing products in Dyspepsia

See all competitors

Product	Company	Stage	Hype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo	Yuhan	Phase 2	27
YM443 + Placebo + Moxifloxacin	Astellas Pharma	Phase 1	29
YM443	Astellas Pharma	Phase 3	40
Cinitapride + domperidone	Eisai	Phase 3	40
Rabeprazole + Rabeprazole + Rabeprazole + Placebo	Eisai	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 3	40
Imonogas + Espumisan	Johnson & Johnson	Phase 3	40
esomeprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	35
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod and Placebo	Novartis	Approved	35
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Gabapentin + Placebo	Pfizer	Phase 3	32
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338 + Placebo	Zeria Pharmaceutical	Phase 3	40
Acotiamide hydrochloride hydrate + Placebo	Zeria Pharmaceutical	Phase 3	44